2024
Incorporation of the central vein sign into the McDonald criteria
Amin M, Nakamura K, Daboul L, O'Donnell C, Cao Q, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prčkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Incorporation of the central vein sign into the McDonald criteria. Multiple Sclerosis And Related Disorders 2024, 93: 106182. PMID: 39622133, PMCID: PMC11779579, DOI: 10.1016/j.msard.2024.106182.Peer-Reviewed Original ResearchCentral vein signDIS criteriaDiagnostic performanceMultiple sclerosisDeep white matter lesionsDiagnosis of multiple sclerosisMulti-center studyInternational multi-center studyWhite matter lesionsNorth American ImagingMcDonald criteriaProspective studyDiagnostic accuracyMRI disseminationDemyelinating diseaseBackground DiagnosisMS diagnosisDiagnostic biomarkersCompare sensitivityLesionsBrain locationsMethods DataBrain imagingBrainSigns
2023
Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort
de Geus M, Leslie S, Wang W, Lam T, Broekman M, Neefjes S, Nairn A, Carlyle B, Arnold S. Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.078466.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentHospital neurology serviceNon-AD diagnosesDiagnostic lumbar puncturePrognosis of ADCerebrospinal fluid biomarkersClinic cohortFurther mechanistic studiesNeurology serviceFDG-PETBrain metabolismFluid biomarkersLumbar puncturePatient cohortClinical indicationsDisease progressionATN biomarkersClinical cohortTreatment responseComplex cohortBackground DiagnosisCSF samplesTreatment efficacyLinear regression analysis
2022
Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease
de Geus M, Leslie S, Ramirez C, Trombetta B, Wang W, Lam T, Gotti C, Roux‐Dalvai F, Droit A, Nairn A, Arnold S, Carlyle B. Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.064314.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentPatient cohortAD-specific biomarkersNon-AD diagnosesPrognosis of ADCerebrospinal fluid samplesNeurology clinicBrain metabolismFluid biomarkersAD progressionCognitive prognosisComplex cohortBackground DiagnosisTreatment efficacyDementia diagnosisLarge-scale patient cohortsPathophysiological processesSpecific biomarkersRegulation of balanceDiagnosisCognitive AssessmentDiseaseCohortBiomarkers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply